Remaxol® in Malignant Mechanical Jaundice

Summary

The trial intends to study the safety and efficacy of Remaxol® (succinate + methionine + inosine + nicotinamide; POLYSAN Ltd., Russia),solution for infusion for the reduction of hyperbilirubinemia in patients with obstructive jaundice caused by tumor (malignancy).

Timeline

Start

2017-04-03

Primary completion

2020-02-03

Completion

2020-03-04

Drugs

Indications